European region having the highest multidrug-resistant (MDR) tuberculosis rates globally, the WHO Regional Office for Europe established ELI, bringing experts from across the region (including countries with both high and low tuberculosis and MDR tuberculosis burden) together to review the major challenges in tuberculosis and MDR tuberculosis laboratory diagnosis and to find solutions to overcome them. The group has recently developed comprehensive new diagnostic algorithms for the WHO European region, applicable to all countries of the region regardless of income or tuberculosis incidence. 2 The emphasis is on the rational use of, ideally, rapid point-of-care molecular tests, or as geographically close to the patient as possible, for timely institution of the most appropriate therapeutic and infection control measures to the benefit of individual patients and public health.
Moreover, all nine high MDR tuberculosis burden countries within WHO's European region receive support from WHO's Supranational Reference Laboratory Network. The European region has benefitted from large-scale projects funded through the EU's FP7 programme and the formation of a network of EU European National Reference laboratories (ERLN) coordinated through the ECDC. All these initiatives are jointly contributing to the understanding of the clinical, epidemiological, behavioural, evolutionary, and genetic factors underlying the emergence, evolution, and clinical consequences of antimicrobial drug resistance, especially MDR tuberculosis and the use of novel diagnostics within quality assured laboratories.
At an international level, the ECDC network and WHO's ELI have been balancing best diagnostic practices, promoting consistent quality across laboratories, training a cadre of new scientists, and developing pan-European diagnostic strategies. 2, 4, 5 More collaborative efforts are needed
Fighting drug-resistant tuberculosis in eastern Europe
We read with great interest the letter from Tomasz Jagielsi and colleagues 1 presenting the Fight Against TB in Central and Eastern Europe (FATE). As the authors point out, eastern Europe is a hotspot for drug-resistant tuberculosis involving countries both within and outside the EU. The correspondence rightly highlights the need for intercountry and regional collaboration; however, it does not mention the existing regional initiatives and networks including WHO's European TB Laboratory Initiative (ELI), 2 the Regional Collaborating Committee on TB, 3 the European Centers for Disease Prevention and Control (ECDC) networks, 4 and professional societies, among others.
Timely and accurate diagnosis of drug-resistant pathogens, especially tuberculosis, is of key importance for rapid treatment initiation, adequate infection control measures, and surveillance purposes. With WHO's that drug resistant tuberculosis "is already a globally established priority for which innovative new treatments are urgently needed". For example, multidrug-resistant Gram-negative pathogens are a priority area for several major funders in a way that drug-resistant tuberculosis is yet to achieve. [2] [3] [4] The high priority given to multidrug-resistant Gram-negative pathogens is partly a combination of the few options for many multidrugresistant Gram-negative pathogens that often affect patients who are immunocompromised with adverse, and often fatal, outcomes even in settings with the most resources. That tuberculosis disproportionately affects deprived populations has remained a key reason for market failure to develop novel antimicrobials. The discovery of new antibiotics for Gram-negative pathogens is a priority for mankind, but this should not lead to the inadvertent relegation of tuberculosis research.
The focus on new antibiotics, while laudable, also underplays the importance of novel interventions beyond antibiotics-research on preventive and alternative curative non-antibiotic treatment options should also be encouraged. 5 Progress has been made in successfully presenting antimicrobial resistance as a major global health challenge; however, we are unlikely to tackle this threat with a list of priority pathogens alone until all relevant elements of society identify the current situation as a crucial issue. Without a major societal shift, the necessary capital to address the economic, scientific, and regulatory factors that contribute to the discovery of new drugs and preventive measures will continue to elude us. The goal of bringing all stakeholders together will not be achieved by excluding multidrugresistant tuberculosis, which is estimated to cause 250 000 deaths annually. 6 We declare no competing interests. as homogenous, neglecting that this population is socially constructed and highly heterogeneous: economic migrants, students, and forced migrants differ with respect to their risk of having, acquiring, or developing tuberculosis. The few studies that provide measures of effectiveness stratified by migrant groups provide important evidence on the differences in yield of tuberculosis in regular migrants compared with refugees or asylum seekers. 5 The primary studies included in the review of Chan and colleagues 1 report such information, allowing for additional subgroup analysis comparing general migrants with refugees to inform decision makers on the effectiveness of post-migration follow-up programmes for different migrant groups. The country of origin of the screened migrant population also affects the effectiveness of tuberculosis screening. 6, 7 Chan and colleagues report that they did not do a subgroup analysis for migrants' countries of origin because of a paucity of information on this variable. This is consistent with other systematic reviews and metaanalyses of the yield of tuberculosis in screening programmes that identified only rudimentary information on migrants' countries of origin in primary reports. 5, 8 However, this information is crucial for the design of sensitive screening programmes. In Germany, for example, the yield of active tuberculosis in screening on entry to the country ranged between 10 per 100 000 Iraqi asylum seekers and 683 per 100 000 Somali asylum seekers-corresponding to the number needed to screen to identify one case of tuberculosis of 9955 in the Iraqi group and 146 in the Somali group. Better reporting in primary studies, and inclusion of information on migrants' countries of origin in tuberculosis screening programmes is urgently needed to develop and assess screening programmes that account for the heterogeneity in migrant populations. KB 
23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia
Motoi Suzuki and colleagues 1 found that 23-valent pneumococcal polysaccharide vaccine (PPV23) showed low to moderate effectiveness against vaccine serotype pneumococcal pneumonia in Japanese people aged 65 years or older treated at four community-based
Post-migration follow-up of migrants at risk of tuberculosis
The systematic review and meta-analysis of Isaac H Y Chan and colleagues 1 on the effectiveness of post-migration follow up of migrants at risk of developing tuberculosis provides urgently needed evidence to inform tuberculosis prevention and control strategies in an era of unprecedented cross-border migration. Their analysis is insightful, but falls short in accounting for the heterogeneity in migrant populations with respect to both reasons for migration and country of origin. Many studies 2-4 on effectiveness of tuberculosis screening treat migrants See Articles page 770
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